Streetbeat News

Products Services

PPH

The VanEck Pharmaceutical ETF (PPH) is a passively managed fund providing exposure to the Healthcare - Pharma segment, launched on 12/20/2011.

Portfolio Pulse from

November 11, 2024 | 12:30 pm

KEYS

Keysight Technologies will showcase new solutions at electronica 2024, including the HD3 oscilloscope and PNA-X vector network analyzer, as well as innovations in RF, digital, power testing, and PathWave Design EDA software.

Portfolio Pulse from

November 11, 2024 | 12:30 pm

JPUS

The article discusses the JPMorgan Diversified Return U.S. Equity ETF (JPUS), a passively managed ETF providing broad exposure to the Large Cap Blend segment of the US equity market. It was launched on September 29, 2015.

Portfolio Pulse from

November 11, 2024 | 12:30 pm

BNO

U.S. oil prices fell below $70 a barrel due to disappointing news from China, the largest crude importer. This has put pressure on oil futures.

Portfolio Pulse from

November 11, 2024 | 12:30 pm

RSPN

The Invesco S&P 500 Equal Weight Industrials ETF (RSPN), launched on November 1, 2006, offers broad exposure to the Industrials sector of the equity market. It is a passively managed ETF.

Portfolio Pulse from

November 11, 2024 | 12:30 pm

CGEN

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, will participate in a fireside chat at the Stifel 2024 Healthcare Conference in New York City.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

NKE

Nike's share price has dropped due to slower growth, but strong fundamentals and the return of a former CEO make it a buy. Despite revenue misses, its free cash flow and share repurchase program support growth and dividend safety.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

ONCY

Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on November 12, 2024, to discuss its third-quarter financial results and recent operational highlights.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

SWTX

SpringWorks Therapeutics will present data from its Phase 2b ReNeu trial on mirdametinib at the 2024 Society for Neuro-Oncology Annual Meeting. The trial shows significant patient responses and quality of life improvements for those with NF1-PN.

Portfolio Pulse from

November 11, 2024 | 12:15 pm

NCNA

NuCana has announced promising initial results from its Phase 1b/2 study of NUC-3373 in combination with Pembrolizumab or Docetaxel. Patients with advanced solid tumors showed significant tumor volume reductions and prolonged progression-free survival.

Portfolio Pulse from

November 11, 2024 | 12:15 pm